wqad

VERIFY: 'Event 201' pandemic exercise didn’t predict COVID-19

Multiple claims on social media say world leaders met for a pandemic simulation right before the first new coronavirus cases were reported. Is this a coincidence or something more? Back in October, a ...
Seeking Alpha

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma (IMMX) today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. A Key Opinion Leader (KOL) event to ...
Yahoo Finance

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage ...
KSDK

VERIFY: 'Event 201' pandemic exercise didn’t predict COVID-19

Multiple claims on social media say world leaders met for a pandemic simulation right before the first new coronavirus cases were reported. Is this a coincidence or something more? Back in October, a ...
Yahoo Finance

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. LOS ANGELES, CA, June 03, 2025 (GLOBE NEWSWIRE) ...
Mena FN

Immix Biopharma Announces Primary Endpoint Met In Positive NXC-201 Interim Results Presented At ASCO, Enabling Path To Best-In-Class Therapy For Relapsed/Refractory AL Amyloidosis

(MENAFN- GlobeNewsWire - Nasdaq) Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint. – NXC-201 met ...